Therefore, genomic rearrangements in prostate cancer, although frequently occurring, are likely dependent on the nature of the AR and TOP2B and are restricted to certain ETS loci except for ETV6. Since genomic lesions of ETV6 are common in leukemia, which does not rely on androgen, deletion of ETV6 might not be dependent on AR signaling. Here, AR is linked to prostate cancer.